CMAJ • July 19, 2005; 173 (2). doi:10.1503/cmaj.045202.
© 2005 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow [Online Appendix]
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Braitstein, P.
Right arrow Articles by Hogg, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braitstein, P.
Right arrow Articles by Hogg, R. S.
Related Collections
Right arrow Liver (including hepatitis and cirrhosis)
Right arrow HIV infection, AIDS

Research
Recherche

Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients

Paula Braitstein, Benita Yip, Valentina Montessori, David Moore, Julio S.G. Montaner and Robert S. Hogg

From the Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland (Braitstein); the British Columbia Centre for Excellence in HIV/AIDS (Braitstein, Yip, Montessori, Moore, Montaner, Hogg); the Departments of Health Care and Epidemiology (Braitstein, Hogg) and of Medicine (Montaner), University of British Columbia, Vancouver, BC.

Correspondence to: Dr. Paula Braitstein, Department of Social and Preventive Medicine, University of Berne, Finkenhubelweg 11, CH-3012 Berne, Switzerland; fax 011-41-31-631-3520; pbraitstein{at}ispm.unibe.ch

Background: We examined the effect of hepatitis C virus (HCV) seropositivity on risk of death among people receiving their first antiretroviral treatment (ART) for HIV infection.

Methods: In British Columbia, the HIV/ AIDS Drug Treatment Program is the only source of free ART. Patients who initiated a triple-drug ART regimen between July 31, 1996, and July 31, 2000, were included if they were ART-naive and had baseline HCV serological data. Outcomes of interest for survival analysis were deaths from natural and HIV-related causes, with a data cutoff of June 30, 2003.

Results: Of 1186 eligible subjects, 606 (51%) were HCV positive and 580, negative. Fewer HCV-positive people were male (78% v. 93%, p < 0.001) and had an AIDS diagnosis at baseline (11% v. 15%, p = 0.028). Their CD4 fraction was significantly higher at baseline (19% v. 16% of T lymphocytes, p < 0.001) but their absolute CD4 counts, log HIV viral load and the type of ART initiated were similar to those of HCV negative people. Of 163 deaths (from natural causes only) during the study period, 118 (19%) were in HCV positive and 45 (8%) in HCV negative patients (p < 0.001); of the 114 deaths attributed to HIV infection, these proportions were 79 (13%) versus 35 (6%; p < 0.001). After adjustment for potential confounders, HCV seropositivity remained predictive of death (adjusted hazard ratio [HR] 2.20, 95% confidence interval [CI] 1.50– 3.21, p < 0.001), especially HIV-related death (adjusted HR 1.75, 95% CI 1.13– 2.72, p = 0.012).

Interpretation: In this population-based HIV treatment program, we found HCV seropositivity to be an independent predictor of mortality, especially death related to HIV infection.




This article has been cited by other articles:


Home page
 Int J EpidemiolHome page
The Antiretroviral Therapy Cohort Collaboration
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Int. J. Epidemiol., December 1, 2009; 38(6): 1624 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
The Data Collection on Adverse Events of Anti-HIV
Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study.
Arch Intern Med, August 14, 2006; 166(15): 1632 - 1641.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
T. Wong and S. S. Lee
Hepatitis C: a review for primary care physicians
Can. Med. Assoc. J., February 28, 2006; 174(5): 649 - 659.
[Abstract] [Full Text] [PDF]